ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2499

Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis

Winifred Badaiki1, Quan Li 2, Tanya Burry 1, Fiona Landells 1, Rachel Gehue 1, Cindy Penney 3, DIanne Codner 1, Amanda Dohey 1, Kerri Smith 1, Fatima Abji 4, Dafna Gladman 5, Darren O'Rielly 1, Vinod Chandran 6 and Proton Rahman 7, 1Memorial University, St. Johns, Canada, 2Toronto Western Hospital, Toronto, Canada, 3Memorial University, St Johns, Canada, 4Memorial University, Toronto, Canada, 5Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 6University Health Network, University of Toronto, Toronto, Canada, 7Memorial University, St. Johns, NL, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: genetics and family studies, psoriasis, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Delay in diagnosis of psoriatic arthritis (PsA) has been shown to contribute to poor radiographic and functional outcome and less successful response to treatment (Haroon et al 2015). Disease interception models are now being proposed to identify siblings at risk of psoriasis (PsC) and PsA among PsA probands, to facilitate earlier management strategies. We set out to determine genetic variants that are likely to be associated with the risk of developing PsC and PsA among siblings of PsA patients.

Methods: A total of 195 probands were identified from well-established PsA cohorts. Family history and clinical assessment of siblings was systematically evaluated, and DNA of siblings was also collected. SNP genotyping was performed using 42 PsA-weighted SNPs on the probands and siblings. 308 siblings were collected (179 unaffected siblings and 129 affected of which 71 had psoriasis without PsA (PsC), and 56 had PsA). For analysis the concordance of genes from probands to sibling pairs (PsA -PsC , PsA-PsA and PsA-PsC or PsA) were compared with PsA-unaffected sibling pair.  Probandwise concordance rates were determined using the formula 2C/(2C+D), in which C is the number of concordant pairs and D is the number of discordant pairs. The concordance difference between two groups were calculated using fisher exact test with an odds ratio (OR) > 1 indicating that the concordance rate in affected siblings was greater than unaffected sibling.

Results: The mean age of the PsA probands at assessment was 48.1 yrs (±14.6) (age of onset of PsC 26.4 (±12.1) and PsA 34.4 (±10.9) yrs). The mean age of PsC siblings at assessment was 53.1 yrs (±14.3) (age onset of PsC at 27.5 (±15.7). The PsA siblings at assessment was 55.2 yrs (±13.4), with age of onset of PsC at 29.4 (±14.9) and PsA 36.1 (±12.9) yrs. Finally, the mean age of assessment of unaffected sibling was 50.2 yrs (±13.2).  A differential concordance rate was noted for three genes with PsC, 4 genes with PsA, six genes for PsC or PsA, compared to the unaffected sibling (Table). In addition, when the concordance of PsA siblings were compared to PsC siblings, LCE3A was more likely (OR 2.6, p=0.015) in PsA and HLA-B*3906 was less likely (OR 0.43, p=0.038) to be shared in PsA .

Conclusion: There is greater concordance of known susceptibility genes among PsA siblings and PsC siblings of PsA probands. The genotype of the PsA probands along with the siblings is helpful in determining siblings at risk and should be considered as a potential biomarker for risk prediction.


sib pair – tablepdf- FINAL


Disclosure: W. Badaiki, None; Q. Li, None; T. Burry, None; F. Landells, None; R. Gehue, None; C. Penney, None; D. Codner, None; A. Dohey, None; K. Smith, None; F. Abji, None; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, BMS, 5, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 5, Galapagos NV, 5, Gilead, 5, GSI, 5, Janssen, 5, Janssen Research & Development, LLC, 2, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5; D. O'Rielly, None; V. Chandran, None; P. Rahman, Amgen, 5, Abbott, 5, Janssen, 2, 5, 8, Novartis, 5, 8, Eli Lilly, 5, 8, Pfizer, 5, 8.

To cite this abstract in AMA style:

Badaiki W, Li Q, Burry T, Landells F, Gehue R, Penney C, Codner D, Dohey A, Smith K, Abji F, Gladman D, O'Rielly D, Chandran V, Rahman P. Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/predicting-risk-of-developing-psoriatic-arthritis-psa-in-siblings-of-patients-with-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predicting-risk-of-developing-psoriatic-arthritis-psa-in-siblings-of-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology